



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 31 July 2023 (#28)

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Before starting your application, attend the 1) Generic Grant Writing Workshop and then the 2) NIH Grant Writing Workshop.

Important Notices

Fogarty-leDEA Mentorship Program (FIMP): Current and former Fogarty D43 trainees and leDEA-affiliated regional investigators develop skills in study design, data management, analysis, interpretation, and dissemination of research involving large HIV clinical databases generated within leDEA. **Application deadline:** October 23, 2023.

Informational webinars:

- Tuesday, August 1 at 9 pm ET/USA
- Thursday, August 3 at 9 am ET/USA
- Friday, August 4 at 9 am ET/USA

Application portal: Apply online, get webinar information and answers to frequently asked questions

NOT-HS-23-018 Notice of Intent to Publish Funding Opportunity Announcements to Understand and Improve Diagnostic Safety in Ambulatory Care. The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable. AHRQ works within the U.S. Department of Health and Human Services (HHS) and with other partners to ensure that the evidence is understood and used. The Agency for Healthcare Research and Quality (AHRQ) intends to publish two Notices of Funding Opportunity (NOFO) to invite proposals focused on understanding and improving diagnostic safety in the heterogeneous ambulatory care environment.

NOT-AA-23-016 Notice of Request for Letters of Interest: NIAAA Alcohol Pharmacotherapy Evaluation Program (APEP). The National Institute of Alcohol Abuse and Alcoholism (NIAAA) is seeking letters of interest (LOIs) for promising medications (both novel compounds and repurposed medications) to evaluate their efficacy and safety in Phase 1 and 2 clinical trials for the treatment of alcohol use disorder (AUD). Clinical trials will be supported by a NIAAA contract and conducted by NIAAA's Alcohol Pharmacotherapy Evaluation Program (APEP). This program includes studies conducted by the NIAAA Clinical Investigations Group (NCIG), Human Laboratory Program (HLAB), and Alcohol Interaction program (ALC InX). Studies supported under this mechanism are designed by the APEP team and utilize established paradigms and protocols developed in collaboration with the medication's stakeholders. APEP trials are generally completed within 1.5 years and are conducted under Good Clinical Practice (GCP). The **LOI must be emailed to Dr. Daniel Falk (falkde@mail.nih.gov) no later than September 15th, 2023.**

[NOT-NS-23-101](#) Notice of Information: High-Priority Principles of Rigorous Research for the Final Receipt Date of NINDS Materials to Enhance Training in Experimental Rigor (METER) Funding Opportunity. The [Office of Research Quality](#) at the National Institute of Neurological Disorders and Stroke (NINDS) is issuing this notice to inform the extramural research community about principles of rigorous biomedical research that have not yet been selected for development into educational units by previous awardees of the [Materials to Enhance Training in Experimental Rigor \(METER\) \(UE5 Clinical Trial Not Allowed\)](#) funding opportunity. One receipt date remains for METER: **October 10, 2023.**

[NOT-NS-23-098](#) Notice of Change to Extend Last Receipt Date for [PAR-21-032](#): "NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)" The purpose of this notice is to extend the expiration date for [PAR-21-032](#): NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed) by one review cycle. An additional receipt date has been added, February 9th, 2024, for new and resubmission applications. This Notice of Funding Opportunity now expires on May 8th 2024.

[NOT-AG-23-045](#) Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: The Harmonized Cognitive Assessment Protocol (HCAP) Network (U24 Clinical Trial Not Allowed). This Notice informs the research community that the National Institute on Aging (NIA) intends to issue a limited competition Request for Applications (RFA) for applications to provide critical network support for advancing development in a specific high-priority area of behavioral and social research on Alzheimer's disease (AD) and AD-related dementias (ADRD): The Harmonized Cognitive Assessment Protocol (HCAP) Network.

Parent Announcements

[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates *Expiration Date: May 8, 2023* **Modified Key Dates** *Expiration Date: May 8, 2024*

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

[NOT-AI-23-053](#) Understanding Immune Evasion in Tickborne Diseases. This Notice of Special Interest (NOSI) invites applications that seek to expand understanding of potential immune evasion mechanisms of tickborne pathogens that contribute to human disease and death. The intent of this NOSI is to encourage applications in the field, including from researchers in other disciplines who may have new perspectives to bring to existing gaps. **This notice applies to application receipt dates on or after October 5, 2023 and subsequent receipt dates through July 16, 2026.**

[NOT-AI-23-058](#) Research on Early Allergy Determinants using Biosamples from the SUNBEAM Birth Cohort. This Notice of Special Interest (NOSI) is to solicit applications proposing studies utilizing available biologic and environmental samples collected as part of the birth cohort study, Systems Biology of Early Atopy (SUNBEAM, [NCT04798079](#)), to discover and advance the understanding of novel and established clinical, environmental, biological, and genetic early-life factors in the development of allergic diseases. Studies using these samples are expected to give a deeper understanding of mechanisms contributing to the development of allergic diseases, disease endotypes, and will identify molecular targets for disease prevention. **This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through July 5, 2026.**

NOT-CA-23-078 Pragmatic Trials in Low Resource Settings. The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting context specific, pragmatic clinical trials in low- and middle-income countries (LMICs). NCI encourages applications for pragmatic clinical trials to generate evidence that directly informs decision-making among patients, providers, health systems, communities, and policy makers in LMICs with the goal of improving efficiency, quality, and access for cancer care in resource-constrained settings. The proposed pragmatic trial should (1) be patient-centered, defined as those that involve patients in the trial design and execution to ensure that trial outcomes are relevant and meaningful to patients; (2) be designed to address local disease burdens and health systems and to incorporate input from LMIC stakeholders whose needs, resources, capacities, and priorities are reflected in the study design; (3) include at least one intervention condition and at least one control or comparison condition. Trial designs may be randomized or non-randomized but must be pragmatic. Applications should propose to develop and test new or existing intervention(s) that currently lack adequate evidence and/or are not well established in LMIC settings. **This NOSI applies to application due dates on or after October 17, 2023, and subsequent receipt dates through November 18, 2025.**

NOT-HL-23-099 Lymphatic System in Health and Disease (R01). This NOSI aims to promote research on the normal biology of the lymphatic system (LS) and ascertain factors that account for individual differences in the LS impacting resilience. Also of interest is research to identify factors that account for individual differences in pathobiology and response to treatments, and understand the mechanisms and potential novel therapeutics for lymphatic diseases (LDs) and secondary heart, lung, blood, and sleep (HLBS) disorders related to lymphatic dysfunction. Further, this notice intends to stimulate lymphatic research at molecular, cellular, tissue, organ, and whole-body levels, and aims to facilitate research on innovations for identifying and intervening in LDs across the lifespan and disease states. The NOSI may also reach a broader community and facilitate multidisciplinary research needed to determine the function and role LS in health, disease prevention, and to identify biomarkers and test prevention and treatment strategies with specific attention to social determinants of health, and both treatment and health inequities. **This notice applies to due dates on or after October 5, 2023, and subsequent receipt dates through September 7, 2026.**

Notice of Funding Opportunity (NOFO)

1. Role of Environmental Stress in the Health Inequities of Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-NS-24-024](#)

Type:01

Application Due Date: November 01, 2023 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Announcement: This Notice of Funding Opportunity (NOFO) invites applications for basic, translational, and clinical research projects that propose to study the role of environmental stress on the health inequities in Alzheimer's Disease Related Dementias (ADRD), including Frontotemporal Dementia (FTD), Lewy Body Dementia (LBD), Vascular Contributions to Cognitive Impairment and Dementia (VCID), and Mixed-Etiology Dementia (MED). Environmental stressors include but are not limited to heat, crowding, air pollution, noise, violence, and psychosocial stress. Many of these environmental stressors are more prevalent in rural and urban disadvantaged communities which also have a higher risk for ADRD. Thus, there is a need to identify environmental stressors that impact health inequities in ADRD and to determine the mechanistic underpinnings of this stress. This NOFO will support mechanistic, translational, and human subject studies to understand the relationship between environmental stressors and health inequities in ADRD. It is expected that these studies will identify environmental stressors related to health inequities in ADRD and their clinical relevance. Ultimately, these studies should accelerate research towards better therapeutic interventions and quality of life.

Budget: NIH intends to commit a total budget of \$3,750,000 per year to fund up to 5 awards, contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$499,999 in direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Research Development and Support Division (RDSD) & Grants Management Office (GMO)
Faculty of Medicine and Health Sciences
009 Kth Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105